<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347333</url>
  </required_header>
  <id_info>
    <org_study_id>08-045</org_study_id>
    <nct_id>NCT01347333</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Liver Tumors</brief_title>
  <official_title>Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the local control rate as well as acute and late toxicity rates of
      stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary
      liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single site, non-randomized, prospective, phase IV trial.

      Composed of 4 patient groups:

        1. Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm

        2. Metastases from neuroendocrine tumors with functional endocrine syndromes

        3. Unresectable hepatocellular carcinoma (HCC)

        4. Unresectable intrahepatic cholangiocarcinoma (IHCC) Data collected will include patient
           demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received
           by adjacent critical normal tissues, tumor recurrence data, and acute and late
           toxicities. Follow up data will be collected during the patient's standard office
           visits. The anticipated duration of this study is 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Tumor Recurrence Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Primary endpoint will be local tumor recurrence rate. Local recurrence is defined as tumor recurrence within the planning target volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Complication Rates</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicities will be assessed using CTCAE grading criteria at specified timepoints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>liver metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary Liver Tumors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiosurgery</intervention_name>
    <description>36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
    <arm_group_label>liver metastases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
    <arm_group_label>Primary Liver Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age &gt;= 18 years

          -  Zubrod performance status of 0-3

          -  Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm

          -  Metastases from neuroendocrine tumors with functional endocrine syndromes for symptom
             palliation

          -  Unresectable hepatocellular carcinoma (HCC)

          -  Unresectable intrahepatic cholangiocarcinoma (IHCC)

          -  Maximum tumor diameter &lt; 6 cm

          -  Adequate liver function:

        Total bilirubin &lt; 3 mg/dL Serum albumin &gt; 2.5 g/dL Serum levels of liver enzymes &lt; 3 times
        the upper limit of normal Normal PT and PTT unless patient is receiving anticoagulant
        medication

        - Signed study-specific consent form

        Exclusion Criteria:

          -  Maximum tumor diameter &gt; 6 cm

          -  Prior radiotherapy to the liver

          -  Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown
             effects of RT on lactating females

          -  Patients with psychiatric or addictive disorder that would preclude obtaining informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bethany G Sleckman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mercy Hospital St. Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>January 22, 2019</results_first_submitted>
  <results_first_submitted_qc>February 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2020</results_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Research</investigator_affiliation>
    <investigator_full_name>Kathy Baglan, MD</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liver Metastases</title>
          <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
Stereotactic body radiosurgery: 36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
        </group>
        <group group_id="P2">
          <title>Primary Liver Tumors</title>
          <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
Stereotactic Body Radiotherapy: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0">No participants were enrolled in the Primary Liver Tumor arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No patients were analyzed in primary liver tumors because none were enrolled to that group.</population>
      <group_list>
        <group group_id="B1">
          <title>Liver Metastases</title>
          <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
Stereotactic body radiosurgery: 36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
        </group>
        <group group_id="B2">
          <title>Primary Liver Tumors</title>
          <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
Stereotactic Body Radiotherapy: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="47" upper_limit="79"/>
                    <measurement group_id="B3" value="63" lower_limit="47" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Local Tumor Recurrence Rate</title>
        <description>Primary endpoint will be local tumor recurrence rate. Local recurrence is defined as tumor recurrence within the planning target volume.</description>
        <time_frame>5 years</time_frame>
        <population>No patients enrolled into primary liver tumor group.</population>
        <group_list>
          <group group_id="O1">
            <title>Liver Metastases</title>
            <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
Stereotactic body radiosurgery: 36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
          </group>
          <group group_id="O2">
            <title>Primary Liver Tumors</title>
            <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
Stereotactic Body Radiotherapy: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
          </group>
        </group_list>
        <measure>
          <title>Local Tumor Recurrence Rate</title>
          <description>Primary endpoint will be local tumor recurrence rate. Local recurrence is defined as tumor recurrence within the planning target volume.</description>
          <population>No patients enrolled into primary liver tumor group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Complication Rates</title>
        <description>Toxicities will be assessed using CTCAE grading criteria at specified timepoints.</description>
        <time_frame>5 years</time_frame>
        <population>This outcome was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Liver Metastases</title>
            <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
Stereotactic body radiosurgery: 36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
          </group>
          <group group_id="O2">
            <title>Primary Liver Tumors</title>
            <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
Stereotactic Body Radiotherapy: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
          </group>
        </group_list>
        <measure>
          <title>Late Complication Rates</title>
          <description>Toxicities will be assessed using CTCAE grading criteria at specified timepoints.</description>
          <population>This outcome was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>At risk for primary liver tumor is 0 because no patients were enrolled to this group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Liver Metastases</title>
          <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
Stereotactic body radiosurgery: 36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
        </group>
        <group group_id="E2">
          <title>Primary Liver Tumors</title>
          <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
Stereotactic Body Radiotherapy: 26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle McFarland, MPH, CHRC</name_or_title>
      <organization>Mercy Research</organization>
      <phone>314-251-8827</phone>
      <email>michelle.mcfarland@mercy.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

